Annons
Initiator Pharma logotypInitiator Pharma
20 november 2026 kl. 07:30(MFN)

INITIATOR PHARMA: Q3 2026 REPORT

Business highlights in Q3 2026

  • In August the Company announced that the European Patent Office (EPO) has granted two new patents – one covering the treatment of pain and one covering an immediate-release oral formulation, adding further patent protection for its lead drug candidate pudafensine in Europe
  • In September the Company announced the appointment of Annette Säfholm, PhD, as Chief Operating Officer (COO) and a member of the management team. She will support the CEO in ongoing business development, partnering and strategic discussions, while contributing to key operational activities across the company.

Business highlights after this reporting period

  • In October the Company announced final dosing of the last planned patient in its Phase IIa clinical proof-of-concept study evaluating pudafensine in women suffering from the genital pain condition vulvodynia.
  • In November the Company announced the resolution to carry out a directed issue of 5,913,170 new shares, each with one warrant, to Klockhuset Investment AB raising gross proceeds of approximately DKK 8.2 million (EUR 1.1 million) before transaction costs. The subscription price is SEK 2.05 per share. Together with existing cash, the proceeds are expected to fund operations into 2028.

Financial Highlights

Third Quarter (2026-07-01 – 2026-09-30)
Net revenue were KDKK 0 (0)
Operating loss, EBIT was KDKK -8,508 (-4,319)
Earnings per share before and after dilution was DKK -0.12 (-0.06)
Cash: KDKK 14,172 (26,245)
Solidity: 0% (88%)
First Nine Months (2026-01-01 – 2026-09-30)
Net revenues were TDKK 0 (0)
Operating loss, EBIT was TDKK -29,439 (-10,815)
Earnings per share before and after dilution was DKK –0.43 (-0.16)

Solidity: equity divided by assets.

The Board of Directors have decided that interim reports will be published in English only.

Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/

Källa: MFNMFN
Annons

0 kommentarer

Kommentera nyheten

När du kommenterar ett pressmeddelande publiceras din kommentar även i en speglad tråd under Börssnack så att alla i forumet kan delta i diskussionen!

Logga in eller skapa ett gratis konto för att kommentera nyheten!